BeyondSpring Inc. (BYSI) News
Track canonical SquawkNews coverage tagged to BYSI, BeyondSpring Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BeyondSpring Unveils Bulin Collaboration Via Subsidiary Sale; Sets ATM for Up to 9.2M Shares
BeyondSpring announced two material agreements: a strategic Share Purchase and Collaboration Agreement tied to the China portion of the DUBLIN-4 Phase 3 trial, and a new at-the-market equity program. The company will tra
GEOPOLITICS | Sep 29, 2026, 11:13 AM UTC
L
Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Beyondspring Inc NASDAQ:BYSI
EQUITY | Sep 29, 2026, 11:09 AM UTC
L
BeyondSpring Inc. (BYSI) Gets FDA Fast Track; Sells China Sub for DUBLIN-4 Support
BeyondSpring received FDA Fast Track for plinabulin plus docetaxel in post-ICI non-squamous NSCLC and agreed to sell its Chinese subsidiary to Biolin, which will fund China enrollment for the global Phase 3 DUBLIN-4 tria
GEOPOLITICS | Sep 29, 2026, 11:09 AM UTC
M
BeyondSpring FDA Fast Track for plinabulin in post-ICI NSCLC
BeyondSpring announces the FDA granted Fast Track designation for plinabulin in post-ICI non-squamous NSCLC, and the company describes a strategic transaction to advance its global Phase 3 DUBLIN-4 trial toward a planned
REGULATION | Sep 29, 2026, 11:08 AM UTC
L
BeyondSpring (BYSI) reports Q2 2026 financial results, corporate update
BeyondSpring (BYSI) reports its second-quarter 2026 financial results and provides a corporate update, according to a TradeXchange Newsdesk alert.
EARNINGS | Aug 14, 2026, 09:15 PM UTC
M
BYSI unit SEED Therapeutics gets FDA orphan drug designation for ST-01156
BeyondSpring’s subsidiary SEED Therapeutics receives FDA orphan drug designation for ST-01156, a small molecule degrader of RNA-binding motif protein 39, for neuroblastoma.
REGULATION | Aug 13, 2026, 03:50 PM UTC